



Company Announcement

Shareholder Update

Thursday, Australia September 20th 2007

Clinuvel Pharmaceuticals Limited wishes to update its shareholders. Despite substantial progress in developing its photo-protective drug CUV1647 as a preventative treatment for a range of UV-related skin disorders, Clinuvel's share price has recently declined to a price of AUD\$0.46, at close of business today.

The current share price is in stark contrast to:

- 5 indications identified by CUV1647
- Current cash position of \$60 million
- Completion of the CUV1647 resorbable implant formulation
- Clinical advancement of two Phase III trials
- Preparation of three additional Phase II trials
- Preparation of an Investigational New Drug (IND) filing in USA

Shareholders should be aware that Absolute Capital Management Holdings Limited (ACMH), an international hedge fund and our largest share holder with over 20% in the company, declared on 19 September 2007 that its funds were distressed.

The fundamentals of Clinuvel and its progress in taking CUV1647 to market are positive and unaffected by events specific to ACMH.

Dr Philippe Wolgen, CEO of Clinuvel said,

"The intense focus of my entire Board and management is on the successful development of CUV1647 as a safe and efficacious pharmaceutical drug."

"We are on track to file for registration for CUV1647 by 2009 and gain market approval. We are well underway with our two Phase III trials and I am very confident about my team's execution ability," he said.

"In the past 21 months we have achieved all of our clinical and corporate targets. We have attracted and developed a management team to advance our core technology. We have in excess of \$60 million in cash."

"Our progress has recently been recognized by independent broker research. ABN AMRO and Intersuisse have valued the company well above current share prices."

"We are well placed to fulfill our strategic objectives successfully."

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited (ASX:**CUV**, XETRA/DAX:**UR9**, ADR:**CLVLY**) is an Australian biopharmaceutical company developing its photo-protective drug CUV1647 as a preventative treatment for a range of UV-related skin disorders as well as in cancer related treatments.

The five indications are:

Indication	Description	Clinical Trial Status
Polymorphic Light Eruption (PLE / PMLE)	Sun poisoning	Phase III trials began May 2007
Erythropoietic Protoporphyrin (EPP)	Absolute sun intolerance	Phase III trials began June 2007
Squamous Cell Carcinoma (SCC) and Actinic Keratosis (AK) in organ transplant patients	Non-melanoma skin cancers / precursor to skin cancers	Phase II trials planned to begin 2007
Solar Urticaria (SU)	Acute anaphylactic reaction to sun	Phase II trials planned to begin 2007
Phototoxicity associated with Photodynamic Therapy (PDT)	Photo-sensitivity associated with cancer treatment	Phase II trials planned to begin 2007

Phase I and II human clinical trials using CUV1647 have demonstrated that the drug is well tolerated and no significant safety concerns have been identified to date.

Following successful conclusion of the development program, Clinuvel will work closely with global regulators to facilitate marketing approval of CUV1647.

-END-

For more information contact:

Colin Mackie
Head of Corporate Development
Clinuvel Pharmaceuticals Limited
Tel: +61 3 9660 4900
investorrelations@clinuvel.com

Clinuvel is an Australian biopharmaceutical company focussed on developing its leading drug candidate, CUV1647, for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for CUV1647 can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development programme for CUV1647 is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place

Level 11 / 330 Collins Street **T +61 3 9660 4900** **www.clinuvel.com**
Melbourne, Victoria 3000 **F +61 3 9660 4999**
Australia